|Board of Directors|
Serge Przedborski, MD, PhD is the Page and William Black Professor of Neurology. He holds a joint appointment in the Departments of Neurology, Pathology and Cell Biology and is the Co-Director of the Center for Motor Neuron Biology and Disease and a faculty member of the Center for Parkinson's disease (PD) and Other Movement Disorders at Columbia University. Dr. Przedborski attended medical school at the Université Libre de Bruxelles (ULB), Belgium, and did his internship and residency in Neurology and Psychiatry at the ULB-Erasme Academic Medical Center, Belgium. He then did a fellowship in movement disorders with Dr. Stanley Fahn at Columbia University, where he became Assistant Professor of Neurology in 1991.
The research conducted in Dr. Przedborski's laboratory is geared toward unraveling the molecular basis of neurodegeneration and devising therapeutic strategies to hamper the processes that cause neuronal death, the source of many debilitating disorders. In keeping with this goal, to what extent and by which mechanisms do cell-autonomous and non-cell autonomous deleterious processes contribute to the demise of specific subpopulation of neurons in neurodegenerative disorders, such as PD represent a main line of research in his laboratory. These research efforts are supported by federal grants from both NIH and the DoD and by private agencies including the Parkinson's Disease Foundation, the Thomas Hartman Foundation, and MDA's Wings Over Wall Street. Dr. Przedborski is a Senior Editor for the Journal of Neuroscience and an Associate Editor of Movement Disorders.
A. Jon Stoessl, CM, MD, FRCPC Professor and Head of Neurology and Director of the Pacific Parkinson's Research Centre and National Parkinson Foundation Centre of Excellence at UBC and Vancouver Coastal Health, and been tapped to co-chair both the third and fourth World Parkinson Congress. He holds a Tier 1 Canada Research Chair in Parkinson's Disease and directs the CIHR Team in Parkinson's and a Pacific Alzheimer Research Foundation Centre grant on Overlap Syndromes Resulting in Dementia.
Dr. Stoessl sits on the editorial boards of numerous journal and has served on a number of scientific advisory boards, including Canadian Institutes of Health Research, Ontario Mental Health Foundation (Chair), Huntington Society of Canada, Tourette Syndrome Association and National Parkinson Foundation. and currently chairs the Interdisciplinary Adjudication Committee of the Canada Research Chairs program. In 2007, he was appointed a Member of the Order of Canada . Dr. Stoessl's research involves the use of positron emission tomography to study Parkinson's disease and related disorders, including the use of imaging as a biomarker, the basis for complications of treatment and mechanisms of the placebo effect. He has published more than 220 papers and book chapters.
MD, PhD (US) received her
M.D. and Ph.D. degrees from the University of Paris VI, in France. She
completed her internship at the Hopital de l'Hotel Dieu in Paris and her PhD
thesis in the laboratory of Jacques Glowinski at the College of France. After
obtaining a position at the CNRS, she joined the laboratory of Ann Graybiel at
MIT and the laboratory of Michael Bronstein at the NIH as a Visiting Scientist.
She held faculty appointments at the Medical College of Pennsylvania and the
University of Pennsylvania before joining UCLA as the Charles H. Markham
Professor of Neurology in 1996. She is currently Chair of the Department of
Neurobiology in the David Geffen School of Medicine at UCLA. She is also
Director of the APDA Advanced Center for Parkinson's Disease Research, Morris
K. Udall Center of Excellence for Parkinson's Disease Research and the Center
for Gene Environment Studies in Parkinson's Disease at UCLA.
Patricia Davies (US) has been a professional conference organizer for about 35 years. She originally worked in the private sector in London, and before moving to the US in 1991 was managing director of Conference Associates and Services Ltd., a company which specialized in the organization of large international conferences, primarily medical. In 1991 she moved to Washington DC to take a position with the World Bank Group and the International Monetary Fund as manager of the office which organizes the organizations' Annual and Spring meetings. She retired from this position in 2007 and was diagnosed with Parkinson's disease early in 2009.
Pat is the current Secretary of the World Parkinson Coalition.
Yoshikuni Mizuno, MD (Japan) is the former Chairman of the Department of Neurology at Juntendo University School of Medicine and currently Professor emeritus of the same University. Having received his MD from the University of Tokyo School of Medicine in 1965, he completed the residency at the Department of Neurology, Northwestern University Medical Center, Chicago, USA in 1973. He returned to Japan in the same year as Assistant Professor of Neurology at the Jichi Medical School, Tochigi, and served as Professor of Neurology at the Juntendo University School of Medicine from 1989 to 2006. After stepping down the chairmanship, he sees patients with Parkinson’s disease and related disorders at different clinics in Tokyo area. Dr. Mizuno has published more than 300 original articles. He is interested in the pathogenesis and treatment of Parkinson’s disease. With his collaborators, he identified the gene (parkin) for the autosomal recessive form of young onset familial Parkinson’s disease. He received many awards for these activities.
Elizabeth "Eli" Pollard has
been with the World Parkinson Coalition from its inception in 2004 and helped
steer the organization, alongside world renowned Parkinsonologist and WPC
founder, Dr. Stanley Fahn. Together they worked to grow WPC Inc. from it's sole
purpose, of hosting a triennial global Congress on Parkinson's disease, to it's
more meaningful place in the community today, as a hub for many of the global
PD organizations to connect and intersect online, on teleconferences, or in
person at the Congresses. Eli is thrilled with the opportunity to meet the
members of the community, to help build the WPC Legacy, and to watch as leading
researchers, clinicians, people with Parkinson's and others work together to bring us closer to finding
the cause(s) of Parkinson's and a cure for the disease.
Eli graduated from Michigan State University with a Bachelor's degree, and the School for International Training with a Master's degree in International & Intercultural Management. She spent most of her 20s living outside the US in Zimbabwe, Switzerland, and Japan with lengthy stays for research or travel in India, China, and Thailand. She lives in Brooklyn, New York with her husband and two rambunctious children who keep her on her toes when she's not knee deep in WPC work.
Dr. Fahn is the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University Medical Center . He is the Past-President of the American Academy of Neurology (AAN). He founded the Movement Disorder Society and served as the Chairman of its Steering Committee and was elected its first president. He was the founding co editor of the journal Movement Disorders, and also served as Associate Editor of Neurology for 10 years.
Dr. Fahn has twice served as Chairman of the Advisory Committee on Peripheral and Central Nervous System Drugs for the Food and Drug Administration. He currently serves on an NIH Oversight Committee to review and give advice on clinical trials on neuroprotection for PD. Dr. Fahn and his scientific colleagues at Columbia University were awarded a Morris K. Udall Parkinson's Disease Research Center of Excellence by the National Institutes of Health in 1999, and it is currently ongoing. Dr. Fahn organized and executed the development of the Unified Parkinson's Disease Rating Scale (UPDRS) and modified and popularized the use of the Schwab England ADL score for global severity of this disease. Both of these rating scores are used worldwide, the former to determine the severity of PD, and the latter as a measure of quality of life. He has participated in many clinical trials of a variety of pharmacotherapeutic agents for PD.
Along with Dr. Ira Shoulson; Dr. Fahn was a co founder of the Parkinson Study Group (PSG), a consortium of clinical investigators dedicated to conduct controlled clinical trials on the prevention and treatment of Parkinson's disease. He has received numerous honors and delivered many titled lectures at a variety of universities around the world.